Maryland researchers produce experimental malaria vaccine

University of Maryland School of Medicine researchers have conducted a new study and have produced an experimental vaccine that can protect adults from malaria for more than a year. Read More »

NIAID begins enrollment in clinical trials of HIV-preventing antibody

Researchers recently began enrollment for the first of two multinational clinical trials, known as the AMP Studies, which are sponsored by the National Institute of Allergy and Infectious Diseases and could provide a safe, tolerable and effective way to prevent HIV infection. Read More »

Study suggests modified cholesterol can inhibit growth of drug-resistant tuberculosis

Researchers from the University of Queensland and University of California San Francisco have found that modified cholesterol can inhibit the growth of the bacterium that causes tuberculosis, a disease that claims a life every 21 seconds. Read More »

NIH organizations issue report on Ebola patient's care

A new report from various organizations under the National Institutes of Health details the clinical course of a 34-year-old American with Ebola virus disease who received intensive supportive care through a clinical trial at the NIH Special Clinical Studies Unit. Read More »

Purdue team creates 3-D map of Zika virus

Purdue University researchers recently created a near-atomic level map of the Zika virus, which could spark vaccines, antiviral drugs, antibodies and a diagnostic test capable of differentiating Zika virus infections from dengue infections. Read More »

NIH commemorates World Tuberculosis Day

The National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently released a statement verifying the organization’s commitment to researching, preventing and treating tuberculosis. Read More »

Study evaluates four-drug TB treatment for HIV/AIDS patients

Johns Hopkins University School of Medicine, the University of North Carolina, and the University of Pennsylvania researchers recently published a report stating there is not any additional benefit for advanced HIV/AIDS patients to receive four tuberculosis drugs in lieu of isonazid alone. Read More »

Blood test predicts chances of TB development

A new study from the South African Tuberculosis Vaccine Initiative at the University of Cape Town suggests that a simple blood test can predict a person’s chances of developing tuberculosis. Read More »

Statins decreases TB treatment time in tested mice

A recent study from the Johns Hopkins University School of Medicine shows that when mice receive statins, typically used to reduce cholesterol, their tuberculosis (TB) infections heal faster than they otherwise would. Read More »

Memory B cells of HIV patients show affinity maturation defects

People with HIV infections experience a wide range of abnormalities in their immune systems, and one of the most recently discovered abnormalities includes affinity maturation defects within the memory B cells. Read More »

Phase 3 of sarcoma chemotherapy trial is discontinued

A clinical trial designed to compare three advanced Kaposi’s sarcoma chemotherapy treatment regimens combined with antiretroviral treatment for AIDS patients will not accept any more participants into its oral chemotherapy drug etoposide tests. Read More »

All study subjects protected with experimental dengue vaccine

All of the subjects who participated in a clinical trial for an experimental dengue virus vaccine showed vastly different results, as the 21 vaccine recipients did not develop the dengue infection, but the 20 placebo recipients did contract the infection. Read More »

Dengue-fever test vaccine shows promise in early clinical trials

A team of scientists at the University of Vermont (UVM) Vaccine Testing Center has been working to develop an efficient, single-dose vaccine designed to protect people from the four strains of dengue fever, and the team said this week that clinical trials on a test vaccine have been promising so far. Read More »

New regimen reduces drug-resistant malaria severity during pregnancy

A recent study funded by the National Institutes of Health and conducted in Uganda found that a new treatment regimen involving two drugs may be able to reduce the severity of drug-resistant malaria during pregnancy. Read More »

NIAID's HOPE study looks at dapivirine vaginal rings to prevent HIV

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), will proceed with the HIV Open-label Prevention Extension (HOPE) Phase 3B trial to study the use of a dapivirine vaginal ring to prevent HIV in women.  Read More »

Genetic clues from Black Death may help scientists fight HIV and hepatitis C

A recent study from the University of Cincinnati suggests that genetic clues from the Black Death may be helpful in developing antiretroviral drug therapy treatments for people with HIV and hepatitis C infections. Read More »

Experimental antibody shields monkeys from Ebola

Researchers from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently developed an antibody that protects monkeys from developing Ebola infections. Read More »

First in-human vaccine study looks at malaria from Plasmodium vivax

Scientists with the Walter Reed Army Institute of Research (WRAIR) recently conducted a human challenge model that tested a vaccine candidate for Plasmodium vivax malaria. Read More »

Study shows antidepressant may relieve cognitive symptoms in HIV patients

The antidepressant Paroxetine has been shown to modestly relief cognitive symptoms in patients who have HIV, including reaction time, decision-making and inflammation. Read More »

Experimental Ebola drug ZMapp requires further research

ZMapp, an experimental treatment for the Ebola virus, may be beneficial to Ebola patients but there is still a lack of data from its developer, Mapp Biopharmaceutical Inc., to determine whether it can be used to treat humans. Read More »